Randomized-clinical trials are needed to assess various interventions combining GLP-1RA with controlled dietary interventions to evaluate health outcomes, such as nutrient status, muscle mass preservation, and overall quality of life
That means that seniors who don't qualify based on a diabetes or other chronic disease diagnosis would have to pay several hundred to thousands of dollars out of pocket for the medications
(The 503A Bulks List is a list of drug substances that the FDA has approved for compounding under section 503A of the Federal Food, Drug, and Cosmetic Act.) If the peptides meet the safety requirements, the committee will recommend reclassifying them onto this list, so they can then be legally prescribed and compounded
This proves particularly beneficial for individuals with type 2 diabetes or other metabolic challenges
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease: findings from the SELECT trial